14 OCT 2015: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today they have received a new allowance of claims from the U.S. Patent Office, focused on technology for Parkinson’s disease diagnostics and treatment. This particular application covers a method of measuring Parkinson’s motor symptoms such as tremor, bradykinesia, and rigidity, and creating visualization maps to assist with programming deep brain stimulation (DBS). Specifically, the allowed claims recognize the unique and proprietary nature of using objective, wearable sensors to measure symptom response to DBS programming, and creating visual programming maps with objective data that clinicians can use to manually adjust settings. In addition, the application of automated programming algorithms to search these maps to determine optimal settings is highly valuable.
GLNT commercialized Kinesia [ https://www.glneurotech.com/kinesia/ ] technology to provide wearable, objective and automated assessment of movement disorder symptoms. That technology is now being deployed in targeted applications such as advanced therapy screening and titration for Parkinson’s disease. “Advanced therapies for Parkinson’s, such as deep brain stimulation, can greatly improve quality of life for patients. However, adjusting the settings on a DBS system to maximize therapeutic benefit within a short programming session can be challenging. This is especially true as, more DBS systems receive regulatory approvals with increased options for contacts and stimulation patterns”, says Joseph P. Giuffrida, PhD, President and Principal Investigator. “Intuitive maps that allow visual representation of symptom response as a function of stimulation settings can provide a unique interface to guide the programming session, improving both the clinician and patient experience.” GLNT has previously launched Kinesia ProView [ https://glneurotech.com/kinesia/products/proview/ ] for creating DBS visualization maps. During a programming session, the patient wears a sensor while data is sent wirelessly to a mobile platform with an app to process objective symptom scores and display them as a function of DBS settings.
About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies [ https://www.glneurotech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.
Media Contact
Maureen Phillips, 216-361-5410 – mphillips@GLNeuroTech.com